International Stem Cell shares rise on distribution agreement. After the bell: Athersys up on positive heart treatment results Print E-mail
By BioMedReports.com Staff   
Wednesday, 28 July 2010 19:05

 

Below is a list of the companies that made news in the healthcare sector on Wednesday, July 28, 2010.


Athersys, Inc. (Nasdaq:ATHX) shot up after the bell after the company announced positive results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.

Shares traded up 34 cents or 12% in the after hours market.

AstraZeneca (NYSE:AZN) after the bell today announced that the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes (ACS). Shares were up $1.05 in extended trading.

News from earlier in the day:

International Stem Cell Corporation (OTCBB:ISCO) its wholly-owned subsidiary, Lifeline Cell Technology (Lifeline) and Sristi Biosciences have entered into a distribution agreement for the Lifeline brand of human cell culture products in India.

Lifeline specializes in development, manufacture and distribution of primary human cells and media and growth factors for optimized culturing of cells, including stem cells. These products are being requested by customers internationally, including in India, which represents one of the fastest growing markets for products of this kind.

Shares of ISCO surged more than 22% or 25 cents, closing the day at $1.37.

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS.ob), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied to the U.S. Food and Drug Administration for Fast-Track designation for Restanza, a novel once-daily oral antibiotic, for the treatment of community acquired bacterial pneumonia (CABP).

Shares of Advanced Life Science gained more than 10% on the news.

ArQule, Inc. (Nasdaq: ARQL) today announced the initiation of a Phase 2, single agent trial with ARQ 197 in gastric cancer by Kyowa Hakko Kirin, its exclusive licensee for the development and commercialization of ARQ 197 in the Asian territory consisting of Japan, China (including Hong Kong), South Korea and Taiwan. Initiation of this trial will trigger a $5 million milestone payment to ArQule from Kyowa Hakko Kirin.

"We welcome the expansion by Kyowa Hakko Kirin of its development program with ARQ 197 into gastric cancer," said Paolo Pucci, chief executive officer of ArQule. "We believe this indication may have particular promise in Asia, where the incidence of this cancer is among the highest in the world and where it is the second most common cause of cancer-related death."

Exact Sciences Corp. (Nasdaq: EXAS) today announced that data being presented this afternoon at the annual meeting of the American Association of Clinical Chemistry (AACC) demonstrates that its methylation specific technology, using a combination of DNA methylation markers, detected 100 percent of colorectal cancers and precancers at a specificity cutoff of 100 percent in a preliminary study with colorectal tissue.

The study data also showed that the methylation specific technology was able to detect fewer than 10 copies of methylated DNA. The technology also demonstrated the ability to discriminate 10 copies of methylated DNA target in an unmethylated target population of 100,000 copies.

Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has now achieved 75% of the required number of per-protocol completers in its ongoing six month pivotal global Phase III study of Generex Oral-lyn(TM), the Company's proprietary buccal insulin spray product. These early results suggest that, should the current trend be maintained through the early 2011 completion date of the treatment phase of all enrolled subjects, the use of Generex Oral-lyn(TM) will support a non-inferiority claim relative to the standard-of-care injectable insulin. This position will be reviewed following a formal interim analysis after the 90-day results for all subjects become available.

Hop-on, Inc. (Pink Sheets:HPNN) in conjunction with Re-Medical has debuted Re-Medical's topical Vitamin C patch on Amazon.

Jay Pignatello, President of Hop-on, "This is the only product of its kind on Amazon.com to date. We are extremely excited about the exposure and potential sales the companies will generate from this patch and future patches. We are also focused on distribution channels with big box retailers."

It is a transdermal delivery patch that was created to eliminate the swallowing of daily supplements and higher dosages. Transdermal delivery refers to the topical delivery and absorption of the patches. This delivery system ensures maximum absorption through the blood stream throughout a 24 hour period, rather than through the intestine or liver whose absorption is questionable.

Marina Biotech, Inc. (NASDAQ:MRNAD) announced today that the Company has acquired the intellectual property of Novosom AG of Halle, Germany for its SMARTICLES liposomal-based delivery system in an all-stock transaction. The transaction further expands Marina's RNA delivery platform IP estate, which now includes DiLA2 delivery platform, tkRNAi (bacterial delivery platform), peptide nanoparticle delivery platform, and the SMARTICLES liposomal delivery platform. This acquisition significantly broadens the number of approaches Marina may take for systemic and local delivery of its proprietary UsiRNA therapeutics. The assets were acquired by Marina for approximately $5 million in unregistered Marina common stock. Additional terms of the agreement were not disclosed.

Nymox Pharmaceutical Corporation (Nasdaq:NYMX) provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.

Radient Pharmaceuticals Corporation (RPC) (AMEX:RPC) announced today its China-based subsidiary Jade Pharmaceuticals Inc. (JPI) signed a letter of intent (LOI) under which JPI will acquire Shanxi BaoTai Pharmaceutical Co., Ltd. (BaoTai), a privately owned pharmaceutical manufacturing company located in Taiyuan China, through a non-taxable merger of business assets. The transaction, assuming all closing conditions are satisfied or waived, is expected to close in mid-November 2010. The transaction combines the strengths of JPI and BaoTai, two highly successful Chinese pharmaceutical companies, into a single formidable enterprise focused on developing cancer-centric products recognized for quality, branded product names and technical leadership.

Also Wednesday:

Abiomed, Inc. (NASDAQ: ABMD) announced today that on Wednesday, August 4, 2010, the Company will release financial results for the first quarter of fiscal 2011.

Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that it will report results for its fourth quarter and fiscal year 2010, ended June 30, 2010 on Tuesday, August 31, 2010 after the market closes.

Advanced Cell Technology, Inc. (OTCBB:ACTC) announced today that it has submitted documentation and a complete response to substantively address th issues raised by the US Food and Drug Administration in connection with the Company's plans to initiate a Phase I/II multicenter study using embryonic stem (ES) cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy (SMD). In November 2009, ACT filed an Investigational New Drug Application to commence treating patients.

Aetna (NYSE: AET) and CVS Caremark (NYSE: CVS) today announced they have entered into a 12-year contract to provide Pharmacy Benefit Management (PBM) services that will further enhance value and service for Aetna's customers and members.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2010.

AtheroNova Inc. (OTCBB: AHRO) AtheroNova Inc. announced that in compliance with all FINRA requirements its trading symbol returned to AHRO.OB as of the opening of the market yesterday, July 27, 2010.

Bionovo, Inc. (Nasdaq: BNVI) announced today that it will release financial results for the second quarter of fiscal year 2010 ended June 30, 2010 on Wednesday, August 4, 2010.

Boston Scientific Corporation (NYSE:BSX) today announced the U.S. and European launches of the Neuroform EZ(TM) Stent System, its fourth-generation intracranial aneurysm stent system designed for use in conjunction with endovascular coiling to treat wide-necked aneurysms.

China BCT Pharmacy Group, Inc., (OTC Bulletin Board: CNBI), a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced that it has further expanded its retail network across Guangxi by opening 12 new retail pharmaceutical stores.

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will release second quarter 2010 financial results after the market closes on Monday, August 16, 2010.

Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended June 30, 2010, on Tuesday, August 3, 2010 at 4:00 pm Eastern Time (ET).

EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) announced that it has entered into an Amended and Restated Employment Agreement with Robert W. Cook, EpiCept's Chief Financial Officer, and completed severance agreements with each of Stephane Allard, M.D., EpiCept's Chief Medical Officer, and Dileep Bhagwat, Ph.D., and Bernard R. Tyrrell, each a Senior Vice President of EpiCept.

Flamel Technologies (Nasdaq:FLML) today announced three new partnership agreements and its financial results for the second quarter of 2010.

Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Wednesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2010 financial results.

Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it will host a conference call on Wednesday, August 4th, at 8:30 AM ET, to discuss its financial results for the second quarter 2010.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that Michael Higgins, Ironwood's chief financial officer and chief operating officer, will present at Wedbush Life Sciences MAC Best Ideas 2010 on Tuesday, August 3, 2010 at 8:35 a.m. Eastern Time at Le Parker Meridien Hotel in New York.

Macada Holding, Inc. (PINKSHEETS: MCDA) announced today that it acquired two new cosmetics formula for eyes, anti-wrinkle and aging skin products for the Bio-Skin line.

The Medicines Company (NASDAQ: MDCO) today announced its financial results for the second quarter of 2010.

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its second quarter 2010 financial results on Wednesday, August 4, 2010 at approximately 4:30 p.m. ET.

Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it has received approval from the United States Patent and Trademark Office (USPTO) for its patent describing a method of treating and preventing infectious diseases, including colds, flu viruses, and bacterial and parasitic infections, using modified and detoxified cobra venom and neurotoxins.

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:
30th Annual Canaccord Genuity Growth Conference on Thursday, August 12, 2010 at 2:00 p.m. Eastern Time at the InterContinental Boston.

Pacific Biomarkers, Inc. (OTCBB: PBMC), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, unveiled its new website on Friday, July 23.

Redpoint Bio Corporation (OTC Bulletin Board: RPBC), a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced the issuance of Patent No. 7,749,730 B2 by the U.S. Patent and Trademark Office entitled "High Throughput Screening Assay for the TRPm5 Ion Channel."

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Gerald T. Proehl, president and chief executive officer, will make a presentation at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5, 2010 at 2:15 p.m. Eastern time (11:15 a.m. Pacific time) at the Sheraton New York Hotel & Towers in New York City.

SDIX (Nasdaq: SDIX) - a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications, expects to release its second quarter results at approximately 4 p.m. ET on Wednesday, August 4, 2010.

Stellar Pharmaceuticals Inc. OTCBB:SLXCF) a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced today that it has now been issued patents ("the patents") that are central to one of its lead products, Uracyst® (a sterile sodium chondroitin sulfate solution, 2%) for the treatment of interstitial cystitis/painful bladder syndrome ("IC/PBS"), by both the Chinese Patent Office and the U.S. Patent and Trademark Office.

Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it will report financial results for the second quarter ended June 30, 2010 on Wednesday, August 4, 2010, after the U.S. financial markets close.

United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended June 30, 2010.

Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor Chief Medical Officer Dr. Daniel Weiss will present an abstract of the results of a pilot study to test the ability of Vicor's PD2i® nonlinear algorithm to detect acute hypovolemia at the AABB 2010 Annual Meeting.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on recent progress in its development programs in hepatitis C virus (HCV) infection cystic fibrosis (CF) and other diseases and reported consolidated financial results for the quarter ended June 30, 2010.

VIASPACE Inc. (OTC Bulletin Board: VSPC), a clean energy company growing Giant King Grass as a low-carbon, renewable biomass crop, reported that Chief Executive Dr. Carl Kukkonen made an invited presentation at the Third Annual World Congress of Industrial Biotechnology held in Dalian, China, July 25-27, 2010, where more than 500 business executives, industry leaders, technical experts, government officials and investors attended from around the world.

ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the second quarter ended June 30, 2010.

Warner Chilcott plc (Nasdaq: WCRX) today announced that it will issue its second quarter 2010 financial results prior to the market opening on Friday, August 6, 2010.

  

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter